TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03221192

Intervention type: OTHER
Intervention: VAS questionnaire
Description: VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, \>3-7 (or \>30-70) as moderate disease and \>7-10 (or \>70-100) as severe disease.

Intervention type: OTHER
Intervention: VAS questionnaire
Description: VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, \>3-7 (or \>30-70) as moderate disease and \>7-10 (or \>70-100) as severe disease.

Intervention type: OTHER
Intervention: SNOT-22 questionnaire
Description: SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.

Intervention type: OTHER
Intervention: SNOT-22 questionnaire
Description: SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.

Intervention type: OTHER
Intervention: Data capture app
Description: Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
Study: NCT02390050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin tablets
Description: Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin tablets
Description: Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin tablets
Description: Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bexagliflozin tablets, placebo
Description: Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
Study: NCT00911287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release
Description: Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
Study: NCT03866161

Intervention type: DEVICE
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure treatment
Study: NCT03912376

Intervention type: DIAGNOSTIC_TEST
Intervention: Quest Hyperspectral Imaging System
Description: In this camera 3 sensors are combined for optimal spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.
Study: NCT01880528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT00517296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Patients began therapy with adalimumab using clinic standards for dosing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS
Description: Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
Study: NCT03377582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both interventions uses exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both interventions uses exercises
Study: NCT04357535

Intervention type: DRUG
Intervention: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)
Description: ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.
Study: NCT03597347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim nebulizer solution
Description: 300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim nebulizer solution
Description: 300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim nebulizer solution
Description: 300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARI eFlow nebulizer system
Description: PARI eFlow nebulizer system
Study: NCT00579033

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Tactile training + sham rTMS
Description: tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tactile training + rTMS
Description: tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
Study: NCT00107653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000-1200mg po daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 micrograms sc/week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000-1200mg po daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 micrograms sc/week for 48 weeks
Study: NCT04131413

Intervention type: DRUG
Group type: OTHER
Intervention: pNGVL4aCRTE6E7L2
Description: The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).

Intervention type: DRUG
Group type: OTHER
Intervention: pNGVL4aCRTE6E7L2
Description: The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).

Intervention type: DRUG
Group type: OTHER
Intervention: pNGVL4aCRTE6E7L2
Description: The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
Study: NCT04392960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetaben
Description: Patients will undergo on the same day:~* 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~* standard assessment of clonal and organ disease;~* echocardiography;~* cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation.
Study: NCT02515747

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: elective percutaneous coronary balloon angioplasty and/or stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass grafting
Description: elective surgical myocardial revascularisation
Study: NCT02344108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspire® Upper Airway Simulation System (Model 3028 IPG )
Description: Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
Study: NCT03507257

Intervention type: DRUG
Intervention: Flortaucipir
Description: All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Flortaucipir
Description: All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Flortaucipir
Description: All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Florbetaben
Description: All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Florbetaben
Description: All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Florbetaben
Description: All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Fluorodeoxyglucose
Description: All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.

Intervention type: DRUG
Intervention: Fluorodeoxyglucose
Description: All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Study: NCT04160182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Conservation Work Simplification Education
Description: The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion.
Study: NCT04527796

Intervention type: OTHER
Intervention: Rehabilitation
Description: During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients.~The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided.
Study: NCT00505271

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity.
Study: NCT06595472

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm Oil Enriched with Plant Sterols
Description: The enriched palm oil contained 52 mg/L of phytosterols, to reach the estimated intake of plant sterols in the treatment group at the level of around 2 g/day \[22\]. The phytosterols used was Vegapure 95 FF® derived from soybean derivatives containing campesterol, stigmasterol and beta-sitosterol. The oil is consumed by respondents as cooking oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Palm oil
Description: The type, composition, and physical appearance of the oil is the same as those of the intervention arm, except that it was not added plant sterol. The oil is consumed by respondents as cooking oil.
Study: NCT03222635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic follow-up
Description: Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
Study: NCT03349723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Single rising dose groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single rising dose groups
Study: NCT03257761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study: NCT00431561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP 12009 10 µM
Description: 10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP 12009 80 µM
Description: 80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide or PCV
Description: temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug delivery system for administration of AP 12009
Description: Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug delivery system for administration of AP 12009
Description: Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of Drug Delivery System
Description: Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of Drug Delivery System
Description: Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
Study: NCT03743441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-level Laser Therapy
Description: LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Low-level Laser Therapy
Description: Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Concentric and eccentric exercises with a total duration of approximately 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise therapy
Description: Concentric and eccentric exercises with a total duration of approximately 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Twenty minutes of cryotherapy applied to the Achilles tendon.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cryotherapy
Description: Twenty minutes of cryotherapy applied to the Achilles tendon.
Study: NCT02568735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: After total hip replacement surgery patient were given either etoricoxib or dexketoprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
Study: NCT01602224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered SQ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Administered SQ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabalumab
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabalumab
Description: Administered IV
Study: NCT04575194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 6 MG/ML [Saxenda]
Description: 3 mg of sc liraglutide daily plus lifestyle intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone-Bupropion Combination
Description: 32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention
Study: NCT03063463

Intervention type: PROCEDURE
Intervention: pneumatic dilation
Description: Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.

Intervention type: PROCEDURE
Intervention: surgical myotomy
Description: This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
Study: NCT02996344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic training
Description: Six online training modules pertaining to suicide prevention in primary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic training
Description: Six online training modules pertaining to suicide prevention in primary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized patient interaction
Description: Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
Study: NCT00774761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/formoterol fumarate
Description: inhalation suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/formoterol fumarate
Description: inhalation suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: inhalation suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: inhalation suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol fumarate
Description: inhalation solution